Physician profile
Maulikkumar Patel
NPI 1831551126
$903.74
in general payments reported to CMS, 2019-2025
13 companies · $312 in 2025
The $312 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16.93 · 2021: $130 · 2022: $146 · 2023: $37.93 · 2024: $261 · 2025: $312.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $611.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $611.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $195.74 | 2022-2025 | Repatha, Repatha |
| Abbott Laboratories | $156.35 | 2023-2025 | Cardiomems, Amplatzer Amulet, Freestyle Libre 3 |
| Medtronic, INC. | $130.00 | 2021 | |
| Cvrx, INC. | $119.23 | 2024-2025 | Barostim Neo System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $115.23 | 2019-2024 | Lifevest |
| Novartis Pharmaceuticals Corporation | $41.42 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $29.32 | 2025 | Uptravi |
| E.R. Squibb & Sons, L.L.C. | $24.13 | 2024 | Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.77 | 2025 | Jardiance |
| Novo Nordisk INC | $19.41 | 2024 | Wegovy |
| Siemens Medical Solutions USA, INC. | $17.89 | 2024 | Somatom Edge Plus |
| Kiniksa Pharmaceuticals International, Plc | $15.75 | 2024 | Arcalyst |
| Boston Scientific Corporation | $15.50 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maulikkumar Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.